List of adverse effects of pazopanib

This is a list of adverse effects of the anti-cancer drug pazopanib, sorted by frequency of occurrence.[1][2][3][4][5]

Very common

edit

Very common (>10% incidence) adverse effects include:

Common

edit

Common (1–10% incidence) adverse effects include:

Uncommon

edit

Uncommon (0.1–1% incidence) adverse effects include:

  • Torsades de pointes
  • Heart failure
  • Liver failure
  • GI perforation (may be fatal)
  • Fistula formation

Rare

edit

Rare (<0.1% incidence) adverse effects include:

  • Reversible posterior leucoencephalopathy syndrome

Notes

edit

Denotes side effects seen at the above frequency only in clinical trials performed in people with renal cell carcinoma.

Denotes side effects seen at the above frequency only in clinical trials done in people with soft tissue sarcomas.

  1. ^ Usually occurs within the first 18 weeks of treatment. 39% of cases develop within the first 9 days of treatment.
  2. ^ This includes leucopenia, thrombocytopenia and neutropenia.
  3. ^ This includes leucopenia, lymphopenia, thrombocytopenia and neutropenia.

References

edit
  1. ^ "Votrient (pazopanib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 27 January 2014.
  2. ^ "VOTRIENT (pazopanib hydrochloride) tablet, film coated" (PDF). DailyMed. GlaxoSmithKline LLC. November 2013. Retrieved 27 January 2014.
  3. ^ "Votrient : EPAR - Product Information" (PDF). European Medicines Agency. Glaxo Group Ltd. 23 January 2014. Retrieved 27 January 2014.
  4. ^ "Votrient 200 mg and 400 mg film coated tablets - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. GlaxoSmithKline UK. 20 December 2013. Retrieved 27 January 2014.
  5. ^ "PRODUCT INFORMATION VOTRIENT® TABLETS" (PDF). TGA eBusiness Services. GlaxoSmithKline Australia Pty Ltd. 25 March 2013. Retrieved 27 January 2014.